within Pharmacolibrary.Drugs.C_CardiovascularSystem.C03C_HighCeilingDiuretics.C03CB02_BumetanideAndPotassium;

model BumetanideAndPotassium
  extends Pharmacolibrary.Drugs.ATC.C.C03CB02;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>C03CB02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Bumetanide is a potent loop diuretic used primarily for the treatment of edema associated with congestive heart failure, liver cirrhosis, and renal disease, including nephrotic syndrome. Potassium is often co-administered to mitigate hypokalemia caused by bumetanide. This combination is used clinically where both diuretic and potassium supplementation are required, and bumetanide is an approved diuretic agent.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic data specific to the bumetanide and potassium combination was found. Estimates are based on published data for bumetanide administered orally in adults with normal renal function.</p><h4>References</h4><ol><li><p>Griffin, M, et al., &amp; Testani, JM (2020). Empagliflozin in Heart Failure: Diuretic and Cardiorenal Effects. <i>Circulation</i> 142(11) 1028–1039. DOI:<a href=\"https://doi.org/10.1161/CIRCULATIONAHA.120.045691\">10.1161/CIRCULATIONAHA.120.045691</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32410463/\">https://pubmed.ncbi.nlm.nih.gov/32410463</a></p></li><li><p>Oberbauer, R, et al., &amp; Turnheim, K (1995). Pharmacokinetics and pharmacodynamics of the diuretic bumetanide in the elderly. <i>Clinical pharmacology and therapeutics</i> 57(1) 42–51. DOI:<a href=\"https://doi.org/10.1016/0009-9236(95)90264-3\">10.1016/0009-9236(95)90264-3</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7828380/\">https://pubmed.ncbi.nlm.nih.gov/7828380</a></p></li><li><p>Jones, RS, et al., &amp; Morris, ME (2020). Contribution of Monocarboxylate Transporter 6 to the Pharmacokinetics and Pharmacodynamics of Bumetanide in Mice. <i>Drug metabolism and disposition: the biological fate of chemicals</i> 48(9) 788–795. DOI:<a href=\"https://doi.org/10.1124/dmd.120.000068\">10.1124/dmd.120.000068</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32587098/\">https://pubmed.ncbi.nlm.nih.gov/32587098</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end BumetanideAndPotassium;
